

Thais Armangue

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/570772/publications.pdf>

Version: 2024-02-01

72
papers

9,483
citations

76326

40
h-index

85541

71
g-index

73
all docs

73
docs citations

73
times ranked

6012
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 157-165.	10.2	2,382
2	Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. <i>Lancet Neurology</i> , The, 2014, 13, 276-286.	10.2	525
3	An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. <i>Lancet Neurology</i> , The, 2019, 18, 1045-1057.	10.2	497
4	Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis. <i>Lancet Neurology</i> , The, 2018, 17, 760-772.	10.2	422
5	Herpes simplex virus encephalitis is a trigger of brain autoimmunity. <i>Annals of Neurology</i> , 2014, 75, 317-323.	5.3	372
6	Pediatric Anti-N-methyl-D-Aspartate Receptor Encephalitisâ€”Clinical Analysis and Novel Findings in a Series of 20 Patients. <i>Journal of Pediatrics</i> , 2013, 162, 850-856.e2.	1.8	362
7	Autoimmune encephalopathies. <i>Annals of the New York Academy of Sciences</i> , 2015, 1338, 94-114.	3.8	322
8	Anti-LGI1â€”associated cognitive impairment. <i>Neurology</i> , 2016, 87, 759-765.	1.1	264
9	Investigations in GABA _A receptor antibody-associated encephalitis. <i>Neurology</i> , 2017, 88, 1012-1020.	1.1	257
10	Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. <i>Multiple Sclerosis Journal</i> , 2015, 21, 866-874.	3.0	241
11	Autoimmune postâ€”herpes simplex encephalitis of adults and teenagers. <i>Neurology</i> , 2015, 85, 1736-1743.	1.1	226
12	Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study. <i>Lancet Neurology</i> , The, 2020, 19, 234-246.	10.2	207
13	Autoimmune Encephalitis in Children. <i>Journal of Child Neurology</i> , 2012, 27, 1460-1469.	1.4	178
14	Paraneoplastic Neurological Syndromes and Glutamic Acid Decarboxylase Antibodies. <i>JAMA Neurology</i> , 2015, 72, 874.	9.0	169
15	Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. <i>JAMA Neurology</i> , 2016, 73, 417.	9.0	152
16	Autoimmune encephalitis as differential diagnosis of infectious encephalitis. <i>Current Opinion in Neurology</i> , 2014, 27, 361-368.	3.6	148
17	Investigations on CXCL13 in Antiâ€”<i>N</i>-Methyl-<sc>D</sc>-Aspartate Receptor Encephalitis. <i>JAMA Neurology</i> , 2015, 72, 180.	9.0	142
18	Encephalitis with mGluR5 antibodies. <i>Neurology</i> , 2018, 90, e1964-e1972.	1.1	139

#	ARTICLE	IF	CITATIONS
19	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	6.0	134
20	Clinical and pathogenic significance of IgG, IgA, and IgM antibodies against the NMDA receptor. <i>Neurology</i> , 2018, 90, e1386-e1394.	1.1	120
21	Human neurexin-3 β antibodies associate with encephalitis and alter synapse development. <i>Neurology</i> , 2016, 86, 2235-2242.	1.1	116
22	Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease. <i>Journal of Neuroinflammation</i> , 2019, 16, 134.	7.2	115
23	Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. <i>Journal of Neurology</i> , 2016, 263, 1349-1360.	3.6	112
24	Janus Kinase Inhibition in the Aicardi-Goutières Syndrome. <i>New England Journal of Medicine</i> , 2020, 383, 986-989.	27.0	109
25	Clinical significance of anti-NMDAR concurrent with glial or neuronal surface antibodies. <i>Neurology</i> , 2020, 94, e2302-e2310.	1.1	94
26	Hashimoto encephalopathy in the 21st century. <i>Neurology</i> , 2020, 94, e217-e224.	1.1	92
27	Use and Safety of Immunotherapeutic Management of <i>N</i> -Methyl-D-Aspartate Receptor Antibody Encephalitis. <i>JAMA Neurology</i> , 2021, 78, 1333.	9.0	91
28	Autoimmune Encephalitis in Postpartum Psychosis. <i>American Journal of Psychiatry</i> , 2015, 172, 901-908.	7.2	88
29	E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 2-13.	1.6	87
30	Epidemiology of NMOSD in Catalonia: Influence of the new 2015 criteria in incidence and prevalence estimates. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1843-1851.	3.0	77
31	International Consensus Recommendations for the Treatment of Pediatric NMDAR Antibody Encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	70
32	Therapeutic options for CTLA-4 insufficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 736-746.	2.9	68
33	Anti-NMDA receptor encephalitis and nonencephalitic HSV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, e458.	6.0	67
34	Paediatric multiple sclerosis and antibody-associated demyelination: clinical, imaging, and biological considerations for diagnosis and care. <i>Lancet Neurology</i> , The, 2021, 20, 136-149.	10.2	60
35	Anti-MOG encephalitis mimicking small vessel CNS vasculitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e538.	6.0	60
36	E.U. paediatric MOG consortium consensus: Part 5 – Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 41-53.	1.6	59

#	ARTICLE	IF	CITATIONS
37	Clinical significance of Kelch-like protein 11 antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	54
38	A novel treatmentâ€responsive encephalitis with frequent opsoclonus and teratoma. <i>Annals of Neurology</i> , 2014, 75, 435-441.	5.3	51
39	Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults. <i>Journal of Neurology</i> , 2019, 266, 806-815.	3.6	47
40	Sleep disorders in anti-NMDAR encephalitis. <i>Neurology</i> , 2020, 95, e671-e684.	1.1	47
41	Late-onset neuromyelitis optica spectrum disorder. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	6.0	44
42	Mouse model of anti-NMDA receptor postâ€herpes simplex encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e529.	6.0	44
43	Neonatal detection of Aicardi GoutiÃres Syndrome by increased C26:0 lysophosphatidylcholine and interferon signature on newborn screening blood spots. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 134-139.	1.1	43
44	Clinical Neuropathology practice guide 4-2013: post-herpes simplex encephalitis: N-methyl-Daspartate receptor antibodies are part of the problem. , 2013, 32, 251-254.		42
45	Paraneoplastic cerebellar ataxia and antibodies to metabotropic glutamate receptor 2. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	39
46	Treatment and outcome of aquaporin-4 antibodyâ€positive NMOSD. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	6.0	37
47	When a serum test overrides the clinical assessment. <i>Neurology</i> , 2015, 84, 1379-1381.	1.1	32
48	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 601-613.	0.9	31
49	Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases. <i>Scientific Reports</i> , 2020, 10, 18291.	3.3	30
50	Clinical features of seronegative, but CSF antibody-positive, anti-NMDA receptor encephalitis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e659.	6.0	30
51	E.U. paediatric MOG consortium consensus: Part 4 â€ Outcome of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 32-40.	1.6	29
52	Encephalitis with Autoantibodies against the Glutamate Kainate Receptors <sc>GluK2</sc>. <i>Annals of Neurology</i> , 2021, 90, 101-117.	5.3	26
53	Neurofilament Light Chain Levels in Anti-NMDAR Encephalitis and Primary Psychiatric Psychosis. <i>Neurology</i> , 2022, 98, .	1.1	25
54	E.U. paediatric MOG consortium consensus: Part 3 â€ Biomarkers of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. <i>European Journal of Paediatric Neurology</i> , 2020, 29, 22-31.	1.6	24

#	ARTICLE	IF	CITATIONS
55	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <sc>CANDLE</sc>/<sc>PRAAS</sc>, <sc>SAVI</sc>, and <sc>AGS</sc>. Arthritis and Rheumatology, 2022, 74, 735-751.	5.6	23
56	Epileptic encephalopathy after HHV6 post-transplant acute limbic encephalitis in children: Confirmation of a new epilepsy syndrome. Epilepsy Research, 2013, 105, 419-422.	1.6	21
57	Toll-like receptor 3 deficiency in autoimmune encephalitis post-herpes simplex encephalitis. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e611.	6.0	18
58	Frequency and relevance of IgM, and IgA antibodies against MOG in MOG-IgG-associated disease. Multiple Sclerosis and Related Disorders, 2019, 28, 230-234.	2.0	18
59	Using Acute Optic Neuritis Trials to Assess Neuroprotective and Remyelinating Therapies in Multiple Sclerosis. JAMA Neurology, 2020, 77, 234.	9.0	17
60	Alexander Disease. Journal of Child Neurology, 2017, 32, 184-187.	1.4	14
61	Chronic inflammatory demyelinating polyneuropathy associated with contactin-1 antibodies in a child. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, .	6.0	13
62	Clinical Case of Anti-N-methyl-d-aspartate Receptor Encephalitis in an 8-Month-Old Patient With Hyperkinetic Movement Disorder. Pediatric Neurology, 2013, 48, 400-402.	2.1	11
63	Central Hypoventilation and Brainstem Dysgenesis. Pediatric Neurology, 2012, 46, 257-259.	2.1	9
64	Absence of GluD2 Antibodies in Patients With Opsoclonus-Myoclonus Syndrome. Neurology, 2021, 96, e1082-e1087.	1.1	9
65	Cerebrospinal Fluid Neopterin in Children With Enterovirus-Related Brainstem Encephalitis. Pediatric Neurology, 2019, 96, 70-73.	2.1	8
66	Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders. Neurology: Neuroimmunology and NeuroInflammation, 2022, 9, .	6.0	8
67	Antibodies in acquired demyelinating disorders in children. Multiple Sclerosis and Demyelinating Disorders, 2016, 1, .	1.1	4
68	Efficacy of baricitinib on chronic pericardial effusion in a patient with Aicardi-Goutières syndrome. Rheumatology, 2022, 61, e87-e89.	1.9	4
69	Antibody-Mediated Encephalitis in Children: Focus on Diagnostic Clues and Acute Symptom Management. Seminars in Pediatric Neurology, 2021, 37, 100873.	2.0	3
70	Myorhythmia-Like Dyskinesia Affecting the Face and Ear Associated With Anti-N-Methyl-d-Aspartate Receptor Encephalitis. Movement Disorders Clinical Practice, 2016, 3, 425-426.	1.5	2
71	Autoimmune Encephalitis in Children. Journal of Pediatric Neurology, 2018, 16, 192-201.	0.2	1
72	Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children. Indian Journal of Pediatrics, 2022, 89, 1031-1033.	0.8	1